Citation: Blood Cancer Journal (2015) 5, e351; doi:10.1038/bcj.2015.77 Published online 2 October 2015 The combination of ruxolitinib and dasatinib was safe and effective in the treatment of concomitant PV and CML in this patient A Zhou1, E M Knoche1, E K Engle1, D A C Fisher1 and S T Oh1 1Division of Hematology, Washington University School of Medicine, St Louis, MO, USA […]
Concomitant JAK2 V617F-positive PV and BCR-ABL-positive CML with ruxolitinib and dasatinib
October 2, 2015 By
Discovery Could Boost New Therapies for Myeloproliferative Neoplasms
July 29, 2015 By
Researchers have discovered a way to potentially make drugs more effective at treating certain blood cancers. Source: Discovery Could Boost New Therapies for Myeloproliferative Neoplasms | Memorial Sloan Kettering Cancer Center
Questions to Ask your Doctor for a PV Appointment
June 26, 2015 By
by Marcy Worthington, Charla Billick, Christine Kelly Kennedy and multiple contributions from members of the Polycythemia Vera Supportive Friends Support Group When we have an appointment scheduled with our doctor (hopefully an MPN Specialist at some point) it is helpful to have a list of questions to be properly prepared. It also helps to know […]
The Fleischman Lab Continues Investigating the Role of Inflammation in MPN
April 5, 2015 By
2015 MPN Research Update by Dr. Angela Fleischman We are continuing to work on the role of inflammation in MPN. The human immune system turns on the immune response when it recognizes invaders such as bacteria or viruses by producing inflammatory proteins, also called cytokines. Cytokines are helpful to fight infection but if the immune […]
PV Reporter Newsletter Feb 2015 – Mega News Day!
February 13, 2015 By
Well, what better way to kick off PV Reporter’s first newsletter of 2015! (yeah I know it is mid February:)….some big news on the MPN research front, new funding programs and a moving patient story. First up, let’s look at the new research – Mutation Order in Tumor Genes Affects Cancer Outcome. MPNs are particularly […]
New $1 Million research funding announced for PV, ET and MF
July 8, 2014 By
MPN Research gains momentum with Increased Funding The MPN Research Foundation and The Leukemia & Lymphoma Society (LLS) are proud to announce that ten new research projects will receive funding through their collaboration, renamed MPN Challenge in 2014. The focus areas for this project were conceived at a meeting of academia and industry convened by […]
Jakafi One Step Closer to Approval for Polycythemia Vera
June 12, 2014 By
Jakafi Improves Symptoms in PV In phase 3 randomized controlled trial, Jakafi (ruxolitinib) improved several key symptoms in polycythemia vera, according to Dr Srdan Verstovsek of MD Anderson Cancer Center in Houston. Results from the RESPONSE trial were presented at the 2014 ASCO (American Society of Clinical Oncology) annual meeting in Chicago. PV is a […]
Synopsis of ASH 2013 Abstract – Peginvera study
March 12, 2014 By
by Dr. Angela Fleischman Synopsis of ASH 2013 Abstract: “Analysis of Molecular Responses and Chromosomal Aberrations in patients with PV treated with Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) in the Peginvera study” by Them et al This abstract describes the chromosomal analysis of PV patients on the Peginvera study (a study investigating a long-acting IFNa which can be […]
Riggins Black Polycythemia Vera Story
January 31, 2014 By
Interferon use in PV – A Patient’s Perspective by Riggins Black Looking back at old CBCs, I found I “might” have had PV since 1971. By the way, this is a good reason for you all to become guardians of your medical records (no one will preserve them as well as you can). Although I’ve always […]
CALR Mutated Essential Thrombocythemia is a distinct disease
December 27, 2013 By
JAK2 or CALR mutation status defines subtypes of ET with substantially different clinical course and outcomes Key Points JAK2 (V617F) mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm CALR mutated essential thrombocythemia is a distinct disease entity not only at molecular level but also with respect to clinical outcomes Abstract Patients with […]
Follow Us!